What makes some cancers more deadly?

April 23, 2014
What makes some cancers more deadly?
Dr Lauren Thurgood is investigating what makes a common form of leukaemia more deadly.

A Flinders University researcher is searching for answers as to why some leukaemia sufferers live a normal lifespan while others succumb to the disease within months.

Dr Lauren Thurgood, based in the Department of Haematology and Genetic Pathology, is studying a common form of leukaemia called (CLL) to better understand why a sub-group of patients with this particular type of cancer respond poorly to treatment.

Comprising about 30 per cent of all leukaemias, CLL is a slow-growing form of the disease in which the bone marrow makes too many .

"I'm looking at proteins in the cancer cells to try to work out why some patients have a more pathogenic disease while other people who have CLL live longer and don't have any problems," Dr Thurgood said.

"We know from previous research that people with a poor prognosis have a that makes them have a more aggressive disease but we still need to understand at a cellular level what that gene defect does to the cells," she said.

"The cancer cells basically talk to surrounding cells in the so we want to know how they interact with the and how they're told to stay alive.

"Once we know how the cells communicate, we could look at developing a targeted drug therapy to stop the interaction, which would essentially prevent the from taking over."

With CLL typically diagnosed in older adults, Dr Thurgood said the disease was set to become more prevalent as the population ages.

"The fact we're living longer means the frequency of the disease is going to skyrocket because a lot more people will be diagnosed with it, therefore any new information will become crucial to prevention and treatment.

"Once we've refined our research methods and we know more about CLL we can apply our knowledge to other leukaemias, including the pathogenic childhood cancers."

Explore further: New potential treatment opportunities for leukemia patients

Related Stories

Boosting immune responses against leukaemia

November 21, 2012

(Medical Xpress)—In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to ...

Leap in leukemia treatment reported by Dartmouth researchers

May 13, 2013

Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively. The research was published online on May 3, 2013, ...

Monoclonal antibody targets, kills leukemia cells

March 25, 2013

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.